Skip to main content
Premium Trial:

Request an Annual Quote

Silence Inks Delivery Tech Evaluation Deal with Mireven

Premium

Silence Therapeutics this week announced that it has struck a deal under which its delivery technologies will be evaluated by Australian microRNA drug developer Mireven for use with its therapeutic candidates.

Silence will formulate a mimic of miR-7 using its three lipid-based delivery technologies: AtuPlex, which is used in the company's phase I siRNA cancer drug Atu-027; DACC, which selectively targets the lung endothelium; and DBTC, which targets liver cells.

Silence will then test the mimics in vitro and in vivo, and is receiving an undisclosed fee.

Additional terms were not disclosed.

The arrangement with Mireven marks the fourth time a miRNA drug company has signed on to try out Silence's delivery technologies. In January, it inked such a deal with Miragen Therapeutics (GSN 1/12/2012); in late 2011, it forged a similar arrangement with Mirna Therapeutics (GSN 10/27/2011); and about a year ago it began working with InteRNA Technologies (GSN 9/15/2011).

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.